Humana Inc. (HUM)
| Market Cap | 47.15B +31.9% |
| Revenue (ttm) | 145.68B +18.3% |
| Net Income | 1.28B -18.8% |
| EPS | 10.59 -18.8% |
| Shares Out | 120.08M |
| PE Ratio | 37.08 |
| Forward PE | 32.02 |
| Dividend | $3.54 (0.90%) |
| Ex-Dividend Date | Jun 26, 2026 |
| Volume | 899,467 |
| Open | 386.67 |
| Previous Close | 391.06 |
| Day's Range | 386.45 - 397.00 |
| 52-Week Range | 163.11 - 428.88 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 418.61 (+6.62%) |
| Earnings Date | Jul 29, 2026 |
About HUM
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and... [Read more]
Financial Performance
In 2025, Humana's revenue was $129.66 billion, an increase of 10.11% compared to the previous year's $117.76 billion. Earnings were $1.19 billion, a decrease of -1.57%.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for HUM stock is "Buy." The 12-month stock price target is $418.61, which is an increase of 6.62% from the latest price.
News
DaVita enters care pact with Humana for chronic kidney disease patients
DaVita (DVA) announced a new value-based care agreement to deliver coordinated care to Humana (HUM) Medicare Advantage members with chronic kidney disease stages 3B-5. The company said, “Launched July...
As Health Insurers Gain Handle On Costs, Stocks Are Soaring Again
Following a parade of health insurance company earnings reports this summer, stocks are rising and costs appear to be under control for now.
Humana names Shantanu Nundy as Chief Medical Officer
Humana (HUM) announced that Shantanu Nundy, M.D., will join the company as Chief Medical Officer, effective August 31. Dr. Nundy will report to Jim Rechtin, Humana President and CEO, and…
Humana Names Dr. Shantanu Nundy as Chief Medical Officer
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced that Shantanu Nundy, M.D., will join the company as Chief Medical Officer, effective August 31. A practicing physician, health...
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humana agrees not to reference Teva's Israel ties at US drug trial
Health insurer Humana has agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly...
Health insurers are dumping Medicare Advantage plans. Here's how many seniors could be affected.
Older adults could be scrambling for new health coverage next year, especially in rural markets that have fewer insurance choices.
Humana Healthy Horizons in Indiana collaborates with HealthStream
Humana (HUM) Healthy Horizons in Indiana, Humana’s Medicaid managed care plan, is collaborating with HealthStream (HSTM). “Expanding access to training is one of the most direct ways we can grow…
Humana Healthy Horizons in Indiana Collaborates with HealthStream to Expand and Strengthen Home Care Workforce
INDIANAPOLIS--(BUSINESS WIRE)--Humana Healthy Horizons in Indiana Collaborates with HealthStream to Expand and Strengthen Home Care Workforce.
James P. Holland to Join Humana as Medicaid President
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced that James “J.P.” Holland will join the company as senior vice president and President of Medicaid, effective August 17. In th...
Humana price target raised to $393 from $316 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Humana (HUM) to $393 from $316 and keeps a Neutral rating on the shares.
Humana’s iCare selected for Family Care, Family Care Partnership in Wisconsin
Independent Care Health Plan, a Humana (HUM) subsidiary, has been selected by the Wisconsin Department of Health Services to serve both the Family Care and Family Care Partnership programs in…
Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Subsidiary iCare Selected for Family Care and Family Care Partnership Contracts Across Southeast Wisconsin.
Morgan Stanley upgrades Humana to Equal Weight on better cost trends
Morgan Stanley analyst Erin Wright upgraded Humana (HUM) to Equal Weight from Underweight with a price target of $370, up from $249. The firm cites improving visibility into Medicare Advantage…
Humana upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Humana (HUM) to Equal Weight from Underweight with a price target of $370, up from $249.
Humana Community Day 2026 Mobilizes Thousands of Employees Nationwide to Support Healthier Communities
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced Humana Community Day 2026, its annual nationwide day of service taking place Wednesday, Aug. 26, 2026, mobilizing thousands of...
Humana price target raised to $370 from $350 at TD Cowen
TD Cowen analyst Ryan Langston raised the firm’s price target on Humana (HUM) to $370 from $350 and keeps a Hold rating on the shares. The firm said while a…
Humana price target raised to $407 from $344 at Barclays
Barclays raised the firm’s price target on Humana (HUM) to $407 from $344 and keeps an Equal Weight rating on the shares.
Piper upgrades Humana to Overweight on enterprise earnings growth
Piper Sandler upgraded Humana (HUM) to Overweight from Neutral with a price target of $463, up from $254. The stock in early trading is down 1% to $362.77. Instead of…
Humana upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler analyst Jessica Tassan upgraded Humana (HUM) to Overweight from Neutral with a price target of $463, up from $254.
Humana upgraded, Las Vegas Sands downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by…
Humana price target raised to $405 from $320 at UBS
UBS raised the firm’s price target on Humana (HUM) to $405 from $320 and keeps a Neutral rating on the shares.
Humana upgraded to Outperform from Market Perform at Leerink
Leerink analyst Whit Mayo upgraded Humana (HUM) to Outperform from Market Perform with a $513 price target Looking at probable earnings power scenarios for 2028, the firm contends that the…
Humana price target lowered to $436 from $441 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Humana (HUM) to $436 from $441 and keeps a Buy rating on the shares. The company reported a solid Q2 beat and…
Humana price target raised to $405 from $340 at Oppenheimer
Oppenheimer analyst Michael Wiederhorn raised the firm’s price target on Humana (HUM) to $405 from $340 and keeps an Outperform rating on the shares following the company’s earnings report. Overall,…